Evidence map›Paper›PMID 32374880›Full record

ArticleBlood advances2020

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

Eduardo Espada, Matthew P Cheng, Haesook T Kim, Ann E Woolley, Jason I Avigan, Edouard Forcade, Maria V D Soares, João F Lacerda, Sarah Nikiforow, Mahasweta Gooptu and 10 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Eduardo EspadaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Matthew P ChengDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Haesook T KimDepartment of Data Sciences, Dana-Farber Cancer Institute, Harvard Chan School of Public Health, Boston, MA; and.
Ann E WoolleyDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jason I AviganDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Edouard ForcadeDepartment of Hematology and Cell Therapy, University Hospital, Bordeaux, France.
Maria V D SoaresInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
João F LacerdaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Sarah NikiforowDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Mahasweta GooptuDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Rizwan RomeeDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Corey S CutlerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Francisco M MartyDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USUniversity of Lisbon · PTDana-Farber Cancer Institute · US

Funding

Single Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI SOIFFER, ROBERT JON · 2019 to 2023
$13.8M
Manipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7M
Reconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5M
NCI NIH HHS P01 CA229092NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560
6 · The paper itself

Abstract

Clinical disease caused by BK virus reactivation is a frequent complication of allogeneic hematopoietic cell transplantation (HCT). Because of the lack of effective antiviral agents, BK virus-specific T cells are emerging as a potential therapy for BK virus disease, but the immune response to BK virus after allogeneic HCT has not been well characterized. Our study describes reconstitution of BK virus-specific T-cell immunity in 77 adult patients after HCT. All patients had urinary symptoms, and urine was tested for BK virus replication; 33 patients were positive for BK virus (cases), and 44 were negative (controls). In BK virus cases, the median time to first positive test was 75 days (range, 2-511). BK virus cases had lower CD4 T-cell counts 3 to 9 months after transplant, but CD8 T-cell counts were similar in cases and controls. BK virus-specific T cells were identified by cytokine flow cytometry in cryopreserved samples collected prospectively. BK virus-specific CD4 T cells producing T helper 1 (Th1) cytokines recovered quickly after HCT. BK virus-specific T cells were detected more frequently in patients with BK virus reactivation at most time points, and CD4 T cells producing Th1 cytokines were more frequent than BK virus-specific cytolytic CD8 T cells. Early detection of interferon-γ+ and cytolytic BK virus-specific CD4 T cells was associated with lower rates of hematuria among cases. Overall, our study describes recovery of BK virus-specific T cells after HCT and the distinct roles for BK virus-specific T cells in the development and resolution of clinical symptoms.

Indexed as

BK VirusHematopoietic Stem Cell TransplantationImmune ReconstitutionAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumans

Identifiers

PMID32374880
PMCPMC7218418
OpenAlexW3023373042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.